WO2010126124A1 - 経皮吸収型製剤 - Google Patents
経皮吸収型製剤 Download PDFInfo
- Publication number
- WO2010126124A1 WO2010126124A1 PCT/JP2010/057659 JP2010057659W WO2010126124A1 WO 2010126124 A1 WO2010126124 A1 WO 2010126124A1 JP 2010057659 W JP2010057659 W JP 2010057659W WO 2010126124 A1 WO2010126124 A1 WO 2010126124A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- adhesive layer
- transdermal
- preparation according
- styrene
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 91
- 239000003814 drug Substances 0.000 claims abstract description 129
- 229940079593 drug Drugs 0.000 claims abstract description 103
- 239000012790 adhesive layer Substances 0.000 claims abstract description 57
- 229920003169 water-soluble polymer Polymers 0.000 claims abstract description 25
- 239000010410 layer Substances 0.000 claims description 78
- -1 fatty acid ester Chemical class 0.000 claims description 63
- 238000010521 absorption reaction Methods 0.000 claims description 30
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 28
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 claims description 28
- 229960002781 bisoprolol Drugs 0.000 claims description 28
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 24
- 239000000194 fatty acid Substances 0.000 claims description 24
- 229930195729 fatty acid Natural products 0.000 claims description 24
- 229960004038 fluvoxamine Drugs 0.000 claims description 20
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 20
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 claims description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 16
- 229920005989 resin Polymers 0.000 claims description 16
- 239000011347 resin Substances 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 16
- 229920002367 Polyisobutene Polymers 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 13
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 12
- 229920001971 elastomer Polymers 0.000 claims description 11
- 239000005060 rubber Substances 0.000 claims description 11
- 239000004014 plasticizer Substances 0.000 claims description 9
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 8
- 239000003431 cross linking reagent Substances 0.000 claims description 8
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 8
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 229920003051 synthetic elastomer Polymers 0.000 claims description 8
- 239000005061 synthetic rubber Substances 0.000 claims description 8
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 claims description 7
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 claims description 7
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 6
- 239000013032 Hydrocarbon resin Substances 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 125000002723 alicyclic group Chemical group 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 229920006270 hydrocarbon resin Polymers 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 229920000136 polysorbate Polymers 0.000 claims description 6
- 235000013772 propylene glycol Nutrition 0.000 claims description 6
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 6
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 5
- 239000003655 absorption accelerator Substances 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- 239000006097 ultraviolet radiation absorber Substances 0.000 claims description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 5
- 239000008158 vegetable oil Substances 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 150000002170 ethers Chemical class 0.000 claims description 4
- 229920003049 isoprene rubber Polymers 0.000 claims description 4
- 150000003505 terpenes Chemical class 0.000 claims description 4
- 235000007586 terpenes Nutrition 0.000 claims description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 3
- 229920006271 aliphatic hydrocarbon resin Polymers 0.000 claims description 3
- 150000005215 alkyl ethers Chemical class 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- FACXGONDLDSNOE-UHFFFAOYSA-N buta-1,3-diene;styrene Chemical compound C=CC=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 FACXGONDLDSNOE-UHFFFAOYSA-N 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 claims description 3
- 229960003338 crotamiton Drugs 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 150000002191 fatty alcohols Chemical class 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 239000001087 glyceryl triacetate Substances 0.000 claims description 3
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
- 150000003903 lactic acid esters Chemical class 0.000 claims description 3
- 229930003658 monoterpene Natural products 0.000 claims description 3
- 235000002577 monoterpenes Nutrition 0.000 claims description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- 229950008882 polysorbate Drugs 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 229930004725 sesquiterpene Natural products 0.000 claims description 3
- 229940032094 squalane Drugs 0.000 claims description 3
- 229940031439 squalene Drugs 0.000 claims description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 3
- 229920003048 styrene butadiene rubber Polymers 0.000 claims description 3
- 229920000468 styrene butadiene styrene block copolymer Polymers 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 229960002622 triacetin Drugs 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 229920002545 silicone oil Polymers 0.000 claims description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 1
- 229960001860 salicylate Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 7
- 230000007774 longterm Effects 0.000 abstract description 3
- 239000000758 substrate Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 53
- 230000009102 absorption Effects 0.000 description 21
- 239000000853 adhesive Substances 0.000 description 20
- 230000001070 adhesive effect Effects 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 14
- 238000000576 coating method Methods 0.000 description 13
- 230000000704 physical effect Effects 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000011248 coating agent Substances 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000005020 polyethylene terephthalate Substances 0.000 description 10
- 229920000139 polyethylene terephthalate Polymers 0.000 description 10
- 238000002156 mixing Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- 239000003522 acrylic cement Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229920001296 polysiloxane Polymers 0.000 description 5
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 5
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 5
- 239000000935 antidepressant agent Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 231100000245 skin permeability Toxicity 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 3
- 239000002876 beta blocker Substances 0.000 description 3
- 229940097320 beta blocking agent Drugs 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000010030 laminating Methods 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000010734 process oil Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- HBKBEZURJSNABK-MWJPAGEPSA-N 2,3-dihydroxypropyl (1r,4ar,4br,10ar)-1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylate Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(=O)OCC(O)CO HBKBEZURJSNABK-MWJPAGEPSA-N 0.000 description 2
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 2
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940100463 hexyl laurate Drugs 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920001083 polybutene Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000005033 polyvinylidene chloride Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CSTRPYAGFNTOEQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;octadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O CSTRPYAGFNTOEQ-MGMRMFRLSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical class NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229920003180 amino resin Polymers 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 230000009876 antimalignant effect Effects 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 230000002763 arrhythmic effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 150000001893 coumarin derivatives Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940031569 diisopropyl sebacate Drugs 0.000 description 1
- 150000002012 dioxanes Chemical class 0.000 description 1
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 1
- 229940113120 dipropylene glycol Drugs 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 150000002462 imidazolines Chemical class 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000010721 machine oil Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 229940083254 peripheral vasodilators imidazoline derivative Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- JWCPZKNBPMSYND-UHFFFAOYSA-N propan-2-yl 4-aminobenzoate Chemical compound CC(C)OC(=O)C1=CC=C(N)C=C1 JWCPZKNBPMSYND-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229940121356 serotonin receptor antagonist Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229940125706 skeletal muscle relaxant agent Drugs 0.000 description 1
- 229940124535 smoking cessation aid Drugs 0.000 description 1
- MSFGZHUJTJBYFA-UHFFFAOYSA-M sodium dichloroisocyanurate Chemical compound [Na+].ClN1C(=O)[N-]C(=O)N(Cl)C1=O MSFGZHUJTJBYFA-UHFFFAOYSA-M 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 239000003784 tall oil Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229920006305 unsaturated polyester Polymers 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to a percutaneous absorption preparation that continuously transfers a certain amount of drug through the skin.
- an oral administration method In order to obtain a drug effect by administering a drug, an oral administration method is usually used, but the transdermal administration method has many advantages over the oral administration method.
- a drug absorbed from the intestine is first metabolized in the liver before it exhibits a drug effect at a desired position, and its amount is decomposed.
- the absorbed drug does not first pass through the liver during circulation in the body, so that its efficacy is not significantly reduced by metabolism in the liver.
- Transdermal administration also has the advantage that the drug effect is sustained and has a certain form of drug release characteristics.
- transdermal administration method side effects are expected to be reduced by maintaining a constant blood concentration by slow release.
- a transdermal preparation capable of being administered over a long period (1 to 7 days) tends to be desired from the viewpoint of patient compliance.
- Bisoprolol is a basic drug, is a ⁇ -blocker that selectively blocks the ⁇ 1 receptor of the sympathetic nervous system and has no intrinsic sympathomimetic action, and is a therapeutic agent for essential hypertension.
- Bisoprolol is currently used only as an oral agent in clinical settings and has a relatively low effect on the bronchus due to its high ⁇ 1 selectivity.
- symptoms such as bradycardia, dizziness, malaise may occur, and from the viewpoint of stabilization of blood concentration over a long period of time and sustained effect, Rather, it is desired to develop a transdermal preparation using a patch or the like.
- Fluvoxamine is also a basic drug, a selective serotonin reuptake inhibitor that acts on the reabsorption of serotonin at the synapse, and an antidepressant.
- SSRIs selective serotonin reuptake inhibitors
- fluvoxamine are associated with side effects such as nausea, diarrhea, and gastrointestinal tracts when orally administered to patients. There are also defects. Therefore, in recent years, administration methods other than oral administration have been studied.
- Patent Documents 1 to 4 disclose a transdermally absorbable preparation capable of stably administering a drug for a long period of time by laminating a skin adhesive layer on a support and a drug reservoir layer containing bisoprolol. ing.
- Patent Document 5 proposes a patch containing a selective serotonin reuptake inhibitor component as a pharmacologically active component.
- Patent Document 6 discloses a drug impermeable backing layer, a drug reservoir layer containing a serotonin receptor antagonist between the backing layer and the drug release layer, and a feeling that can control the release of the drug.
- a transdermal therapeutic device having at least three layers comprising a drug release layer comprising a pressure-sensitive adhesive layer is disclosed.
- this document neither contains a basic drug at a high concentration nor provides a means for realizing it.
- an object of the present invention is to allow a basic drug to be released from a preparation for a long period (1 to 7 days) at a constant and constant concentration, and further, a large amount of the drug is contained in the preparation. Nevertheless, it is an object of the present invention to provide a percutaneously absorbable preparation with little decrease in the drug content with time and easy manufacturing process.
- the present inventors have a configuration having a pressure-sensitive adhesive layer containing a basic drug and a water-soluble polymer on the support side in a transdermal preparation, The present inventors have found that it is possible to contain a basic drug at a high concentration and have completed the present invention.
- the present invention relates to a transdermal preparation having a support and an adhesive layer, wherein the adhesive layer contains a basic drug and a water-soluble polymer. Furthermore, the present invention provides the transdermal preparation, wherein the pressure-sensitive adhesive layer comprises a plurality of layers, wherein the pressure-sensitive adhesive layer is a drug reservoir layer containing a basic drug and a water-soluble polymer, and the base
- the present invention relates to the above-mentioned percutaneous absorption preparation comprising the above-mentioned drug reservoir layer containing 10 to 60% by mass of a sex drug and a skin adhesive layer.
- the present invention also relates to the transdermal preparation, wherein the basic drug is bisoprolol.
- the present invention relates to the transdermal preparation, wherein the basic drug is fluvoxamine.
- the present invention also relates to the transdermal preparation, wherein the water-soluble polymer is one or more selected from cellulose derivatives, polyvinyl pyrrolidone, and aminoalkyl (meth) acrylate copolymers.
- the present invention relates to the transdermal preparation, wherein the cellulose derivative is hydroxypropylcellulose.
- the present invention also relates to the transdermal preparation, wherein the weight ratio of the drug to the water-soluble polymer in the drug reservoir layer is 15:85 to 70:30.
- the present invention relates to the transdermal preparation, wherein the skin adhesive layer contains a styrene-isoprene-styrene block copolymer.
- the skin adhesive layer further contains one or more selected from the group consisting of a synthetic rubber other than the styrene-isoprene-styrene block copolymer, a tackifier resin, and a plasticizer. It relates to the transdermal preparation.
- the synthetic rubber other than the styrene-isoprene-styrene block copolymer is selected from the group consisting of polyisobutylene, isoprene rubber, styrene-butadiene-styrene copolymer, and styrene-butadiene rubber.
- the tackifier resin may be one or more selected from the group consisting of rosin derivatives, alicyclic saturated hydrocarbon resins, aliphatic hydrocarbon resins, terpene resins, and maleic resins. It is related with the said percutaneous absorption type preparation.
- the plasticizer is petroleum oil, squalane, squalene, vegetable oil, silicone oil, dibasic acid ester, liquid rubber, liquid fatty acid ester, diethylene glycol, polyethylene glycol, salicylic acid glycol, propylene glycol, diethylene glycol,
- the percutaneously absorbable preparation is one or more selected from the group consisting of propylene glycol, triacetin, triethyl citrate, and crotamiton.
- the pressure-sensitive adhesive layer is one or more selected from the group consisting of a solubilizer, a transdermal absorption accelerator, an antioxidant, a filler, a crosslinking agent, an antiseptic, and an ultraviolet absorber.
- the said percutaneous absorption-type formulation which contains further. Furthermore, the present invention provides that the solubilizer and / or absorption enhancer is a saturated or unsaturated, cyclic, linear or branched fatty acid, fatty alcohol, fatty acid ester, amide having 6 to 20 carbon chains.
- Ethers aromatic organic acids, aromatic alcohols, aromatic organic acid esters and ethers, and lactic acid esters, acetate esters, monoterpene compounds, sesquiterpene compounds, azone, azone derivatives, pyrothiodecane, Glycerin fatty acid esters, propylene glycol fatty acid esters, sorbitan fatty acid esters (Span type), polysorbate type (Tween type), polyethylene glycol fatty acid esters, polyoxyethylene hydrogenated castor oil type, polyoxyethylene alkyl ethers, sucrose fatty acid Esters and plants About one or the transdermal preparation is more members selected from the group consisting of an oil.
- the present invention also relates to the transdermal preparation, wherein the ratio of the thickness of the drug reservoir layer to the skin adhesive layer is 1: 3 to 5: 1. Furthermore, the present invention relates to a method for producing the transdermal absorption preparation by laminating a drug reservoir layer and a skin adhesive layer.
- the percutaneous absorption type preparation of the present invention is easy to manufacture, allows the drug to be transdermally absorbed at a stable skin permeation rate over a long period of time, has excellent drug stability over time, and adheres to the skin. It is extremely useful for the treatment of a wide range of diseases because of its superior properties and low skin irritation.
- FIG. 1 is a graph showing the results of a hairless mouse skin permeability test.
- FIG. 2 is a graph showing the results of a human skin permeability test.
- the transdermally absorbable preparation of the present invention is a patch comprising a support and an adhesive layer, wherein the adhesive layer contains a basic drug and a water-soluble polymer.
- the pressure-sensitive adhesive layer is divided into a plurality of layers of two or more, and a skin adhesive layer is present as a layer farthest from the support for sticking to the skin,
- the drug reservoir layer is preferably present between the support and the skin adhesive layer in terms of sustained release of the drug.
- the support of the percutaneous absorption preparation of the present invention is not particularly limited as long as it can carry the pressure-sensitive adhesive layer, and a stretchable or non-stretchable support can be used.
- a stretchable or non-stretchable support can be used.
- woven fabric, knitted fabric, non-woven fabric, polyurethane, polyester, polyvinyl acetate, polyvinylidene chloride, polyethylene, polyethylene terephthalate, aluminum sheet or the like, or a composite material thereof, or a laminate thereof is selected.
- a stretchable or non-stretchable sheet made of polyethylene terephthalate is preferable.
- the pressure-sensitive adhesive layer in the transdermal preparation of the present invention contains a drug and a water-soluble polymer.
- the water-soluble polymer is not particularly limited, and examples thereof include cellulose derivatives (hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, carboxymethylcellulose, methylcellulose, etc.), polyvinylpyrrolidone, polyvinyl alcohol, and aminoalkyl (meth) acrylate copolymers. .
- low melting point such as bisoprolol and fluvoxamine
- low melting point can maintain a large amount (high concentration) of basic drugs, good drug content stability, and good physical properties of the adhesive layer (aggregation) Hydroxypropyl cellulose, polyvinyl pyrrolidone, and aminoalkyl (meth) acrylate copolymers are preferably used from the viewpoint of good properties and no bleeding / cold flow.
- the pressure-sensitive adhesive layer of the present invention preferably contains no water or a lower alcohol having 1 to 6 carbon atoms because it can ensure physical properties (good cohesion and no bleeding / cold flow). Further, the molecular weight (display viscosity) of the water-soluble polymer affects the physical properties of the pressure-sensitive adhesive layer such as cohesive force and hardness.
- the molecular weight (display viscosity) of hydroxypropylcellulose is in the range of 1.0 mPa ⁇ s to 4000 mPa ⁇ s, more preferably 1.0 mPa ⁇ s to 400 mPa ⁇ s.
- the drug used in the transdermally absorbable preparation of the present invention is not particularly limited, and specifically, hypnotic / sedative, antipyretic / anti-inflammatory analgesic, steroidal anti-inflammatory agent, stimulant / stimulant, neuropsychiatric agent, Hormonal agent, local anesthetic agent, urinary organ agent, skeletal muscle relaxant agent, reproductive organ agent, antiepileptic agent, autonomic nerve agent, antiparkinsonian agent, diuretic agent, respiratory accelerator, antimigraine agent, antihistamine agent, Bronchodilators, cardiotonic agents, coronary vasodilators, peripheral vasodilators, smoking cessation aids, antihypertensive agents, arrhythmic agents, anti-malignant ulcer agents, hyperlipidemia agents, hypoglycemic agents, peptic ulcer treatment agents, benefits Bile, gastrointestinal motility improver, liver disease agent, antiallergic agent, antiviral agent, antibiotic agent, habitual addiction agent, appetite suppressant, chemotherapeutic agent
- a blood pressure lowering agent ⁇ blocker, ⁇ blocker, Ca antagonist, ACE inhibitor, angiotensin II receptor antagonist
- ⁇ -blockers are preferred, and bisoprolol is most preferred because of the remarkable effects of the present invention.
- a neuropsychiatric agent an antipsychotic drug, an antidepressant drug, an antidepressant drug, an anxiolytic drug
- an antidepressant drug is particularly preferable.
- the drug is used as a free base or a pharmacologically acceptable salt.
- the pharmacologically acceptable salt is not particularly limited. For example, hydrochloride, hydrobromide, nitrate, sulfate, phosphate, formate, acetate, trifluoroacetate, propionate , Lactate, tartrate, oxalate, fumarate, maleate, citrate, malonate, methanesulfonate and the like.
- the content of the drug blended in the transdermally absorbable preparation of the present invention is usually an adhesive so that a therapeutically effective amount of drug can be administered transdermally over a long period (1 to 7 days). It is in the range of 10 to 60% by mass, preferably 20 to 50% by mass, more preferably 30 to 50% by mass, based on the total amount of the layer or drug reservoir layer.
- the drug can be contained in the drug reservoir in a dissolved state, a supersaturated crystal state, or a dispersed state.
- the content of the drug blended in the transdermally absorbable preparation of the present invention is 10% by mass or less based on the total amount of the adhesive layer or the drug reservoir layer, sufficient skin permeation of the drug over the administration period of the preparation If the amount is 60% by mass or more, sufficient cohesive force as a patch cannot be maintained or content stability may be lowered. Since this percutaneous absorption preparation contains a water-soluble polymer, it can retain a large amount of highly polar basic drugs such as bisoprolol and fluvoxamine, or a pharmaceutically acceptable salt thereof, and the content can be reduced. Few.
- the content ratio of the drug to the water-soluble polymer in the adhesive layer or the drug reservoir layer is determined depending on the stability of the drug over time and the physical properties of the adhesive layer (ensuring cohesiveness, bleeding, cold flow). 15:85 to 70:30, preferably 25:75 to 55:45, and more preferably 35:65 to 55:45.
- the adhesive layer has a drug reservoir layer containing a basic drug and a water-soluble polymer, and a skin adhesive layer laminated on the drug reservoir layer and in contact with the skin
- the percutaneous absorption-type preparation of the present invention may further have a plurality of layers provided between the support and the drug reservoir layer or between the drug reservoir layer and the skin adhesive layer as long as the object of the present invention is achieved.
- the base of the skin adhesive layer is not particularly limited.
- a rubber-based adhesive, a silicone-based adhesive, an acrylic adhesive, and the like can be used, but it is preferable to include a rubber-based adhesive as an adhesive component.
- a styrene-isoprene-styrene block copolymer is particularly preferably used.
- the water-soluble polymer used in the drug reservoir layer has a high polarity
- the rubber-based adhesive component is composed of a monomer component having no such functional group.
- the chemical properties are very different.
- the drug is bisoprolol or fluvoxamine
- a highly polar bisoprolol or fluvoxamine drug reservoir is obtained by laminating a skin adhesive layer of a rubber-based adhesive component and a drug reservoir layer containing a water-soluble polymer. Transition from the skin layer to the skin adhesive layer can be effectively controlled, and bisoprolol and fluvoxamine can be percutaneously absorbed stably for a long time.
- the content of the styrene-isoprene-styrene block copolymer in the skin adhesive layer is 5% by mass or less, sufficient permeability and cohesive force as a patch tend not to be maintained, and if the content is 30% by mass or more, it is affixed. 5-30% by mass is preferable because sufficient adhesive strength as an agent cannot be maintained.
- the skin adhesive layer of the transdermally absorbable preparation of the present invention may contain other synthetic rubber in addition to the styrene-isoprene-styrene block copolymer, and the synthetic rubber is not particularly limited.
- Polyisobutylene, isoprene rubber, styrene-butadiene-styrene copolymer, styrene-butadiene rubber, polysiloxane, etc. can be suitably used, and one of these can be used alone, or two or more can be used in combination. Can do.
- polyisobutylene is particularly preferable, and it is more preferable to use a combination of two or more polyisobutylenes having different molecular weights.
- the content of the synthetic rubber other than the styrene-isoprene-styrene block copolymer in the skin adhesive layer is preferably 1 to 30% by mass, and more preferably 5 to 20% by mass.
- the adhesiveness to the skin is improved depending on the composition ratio. It can be changed freely. For example, if the blending ratio of styrene-isoprene-styrene block copolymer is increased, the adhesive strength can be weakened. Conversely, increasing the blending ratio of polyisobutylene can increase the adhesive strength.
- SIS styrene-isoprene-styrene block copolymer
- PIB polyisobutylene
- the skin adhesive layer of the present invention desirably contains a tackifying resin when the adhesive force applicable for at least 12 hours is insufficient
- the tackifying resin that can be used is not particularly limited, Rosin derivatives (eg, rosin, glycerin ester of rosin, hydrogenated rosin, glycerin ester of hydrogenated rosin, pentaerythritol ester of rosin), alicyclic saturated hydrocarbon resins (eg, Alcon (registered trademark) P-100, Arakawa Chemical Industries), aliphatic hydrocarbon resins (for example, Quinton (registered trademark) B170, Nippon Zeon), terpene resins (for example, Clearon (registered trademark) P-125, Yasuhara Chemical), maleic resin, and the like.
- Particularly preferred are hydrogenated rosin glycerin esters, alicyclic saturated hydrocarbon resins, and terpene resins.
- tackifier resins may be used alone or in combination of two or more.
- the blending amount is not particularly limited, but is preferably 10 to 60% by mass, more preferably 20 to 60% by mass, and particularly preferably 30 to 50% by mass in the skin adhesive layer.
- the skin adhesive layer of the transdermal absorption preparation of the present invention may contain a plasticizer.
- a plasticizer Petroleum oil (For example, paraffinic process oil, naphthenic process oil, aromatic process oil etc.), squalane, squalene, vegetable oil (for example, olive oil, camellia oil, castor oil) , Tall oil, peanut oil), silicon oil, dibasic acid esters (eg, dibutyl phthalate, dioctyl phthalate, etc.), liquid rubber (eg, polybutene, liquid isoprene rubber), liquid fatty acid esters (isopropyl myristate, hexyl laurate) , Diethyl sebacate, diisopropyl sebacate), diethylene glycol, polyethylene glycol, glycol salicylate, propylene glycol, dipropylene glycol, triacetin, triethyl citrate, crotamiton, etc. It is. Liquid
- plasticizers may be used alone or in combination of two or more.
- the blending amount of these plasticizers is not particularly limited, but is preferably 5 to 50% by mass, more preferably 10 to 40% by mass, and particularly preferably 20 to 30% by mass in the skin adhesive layer. preferable.
- a solubilizer, a transdermal absorption accelerator, an antioxidant, a filler, a crosslinking agent, a preservative, an ultraviolet absorber, and the like can be blended. Any solubilizer may be used as long as it is a compound having a dissolving action on a drug.
- the absorption enhancer may be any compound that has been conventionally recognized as having an absorption promoting action on the skin.
- the solubilizer and / or absorption enhancer is not particularly limited.
- aromatic organic acid aromatic alcohol
- aromatic Group organic acid esters or ethers they may be saturated or unsaturated, and
- Antioxidants are not particularly limited, but tocopherol and their ester derivatives, ascorbic acid, ascorbic acid stearate, nordihydroguaiaretic acid, dibutylhydroxytoluene (BHT), butylhydroxyanisole are preferred;
- calcium carbonate, magnesium carbonate, silicate eg, aluminum silicate, magnesium silicate, bentonite, kaolin, etc.
- silicic acid barium sulfate, calcium sulfate, calcium zincate, zinc oxide, oxidation Titanium
- the crosslinking agent is not particularly limited, but is thermosetting resin such as amino resin, phenol resin, epoxy resin, alkyd resin, unsaturated polyester, isocyanate compound, block isocyanate compound, Machine-based crosslinking agent, inorganic crosslinking agents such as metal or metal compound is desirable.
- the preservative is not particularly limited, but ethyl paraoxybenzoate, propyl paraoxybenzoate, and butyl paraoxybenzoate are preferable;
- the ultraviolet absorber is not particularly limited, but p-aminobenzoic acid derivatives, anthranilic acid derivatives , Salicylic acid derivatives, coumarin derivatives, amino acid compounds, imidazoline derivatives, pyrimidine derivatives, and dioxane derivatives are preferred.
- the amount of each of the above-mentioned solubilizer, percutaneous absorption accelerator, antioxidant, filler, cross-linking agent, preservative, and ultraviolet absorber is not particularly limited, but the solubilizer, percutaneous absorption accelerator, antioxidant
- the total amount of filler, cross-linking agent, preservative and UV absorber is based on the total amount of components in the adhesive layer, or converted separately for the drug reservoir layer and skin adhesive layer, and based on the total amount of components contained in each layer
- the content is preferably 0.01 to 20% by mass, more preferably 0.1 to 10% by mass, and particularly preferably 0.1 to 5% by mass.
- the transdermal preparation of the present invention is not particularly limited, for example, between the support and the drug reservoir layer, or between the drug reservoir layer and the skin adhesive layer, but an acrylic adhesive, a rubber adhesive, and the like. Additional layers such as agents, water soluble polymers, controlled release membranes, etc. can also be provided.
- the thickness of the drug reservoir layer is not limited as long as it can contain and retain a sufficient amount for administering a therapeutic amount of drug for a predetermined period (1 to 7 days), preferably 25 to 400 ⁇ m, 50 to 300 ⁇ m is more preferable.
- the thickness of the skin adhesive layer is not particularly limited as long as the preparation can be reliably applied during the application period and the drug release rate can be controlled, but is preferably 10 to 200 ⁇ m, more preferably 20 to 150 ⁇ m.
- the total thickness of the pressure-sensitive adhesive layer including the drug reservoir layer and the skin adhesive layer is not particularly limited, but is preferably 35 to 600 ⁇ m and more preferably 70 to 450 ⁇ m in that it can be applied comfortably without a sense of incongruity. preferable.
- the ratio of the thickness of the drug reservoir layer and the skin adhesive layer can be arbitrarily set in consideration of the stability of the preparation, the release control of the drug, and the sticking property, but usually it is 1: 5 to 5: 1. A range of 1: 3 to 5: 1 is preferable.
- the pressure-sensitive adhesive layer of the patch of the present invention may have a release sheet on the surface in contact with the skin opposite to the support.
- a release sheet for example, films, such as polyester, such as a polyethylene terephthalate, a polyvinyl chloride, a polyvinylidene chloride, a laminated film of fine paper and polyolefin, etc. are mentioned.
- These release sheets preferably have a silicone treatment applied to the surface that contacts the pressure-sensitive adhesive layer. The release sheet can be easily peeled off from the pressure-sensitive adhesive layer at the time of use by the silicone treatment.
- the method for producing the transdermally absorbable preparation of the present invention is not particularly limited, but as one aspect thereof, for example, a water-soluble polymer and a drug are dissolved in a solvent such as water or ethanol, and the resulting solution is placed on a release film After coating and drying, a support is adhered to the drug reservoir layer, while a solution in which styrene-isoprene-styrene block copolymer, synthetic rubber, tackifying resin, and plasticizer are dissolved in an organic solvent is prepared. It can be manufactured by applying onto a release sheet and drying to form a skin adhesive layer, peeling the release film from the previously obtained drug reservoir layer, and bonding them together.
- a solvent such as water or ethanol
- the transdermal preparation of the present invention Using the transdermal preparation of the present invention, basic drugs such as bisoprolol and fluvoxamine can be stably administered over a long period (1 to 7 days). That is, the percutaneous absorption type preparation having the configuration of the embodiment of the present invention can maintain a high skin permeation rate (Flux value) with little variation with time since the start of application, and stably maintain the blood concentration for a long time. It is excellent in terms of compliance in the treatment of hypertension and depression.
- Flux value skin permeation rate
- the two layers are separately formed by the usual solvent coating method, and further, because of its excellent adhesive force and less skin irritation, Even if it is applied for a long time, it does not peel off, it does not cause skin irritation, and the drug content is less decreased with time.
- Examples 1-14 Ethanol was added to each polymer and dissolved so that the blending ratio shown in the above recipe table was obtained, and then bisoprolol or fluvoxamine was added and stirred sufficiently to obtain a coating solution. Next, after apply
- the percutaneous absorption preparations (Examples 1 to 14) of the present invention were obtained by bonding to a polyethylene terephthalate support with a predetermined thickness (200 ⁇ m).
- Comparative Examples 1-5 Bisoprolol or fluvoxamine was added to an acrylic pressure-sensitive adhesive solution (-COOH group-containing type or -OH group-containing type, solvent: ethyl acetate / toluene), and stirred sufficiently to obtain a coating solution. Next, after apply
- the percutaneous absorption preparations of Comparative Examples 1 to 5 were obtained with a predetermined thickness (200 ⁇ m) and further laminated with a polyethylene terephthalate support.
- Comparative Examples 6-8 Styrene-isoprene-styrene block copolymer, polyisobutylene (high molecular weight), polyisobutylene (low molecular weight), alicyclic saturated hydrocarbon resin, and liquid paraffin were dissolved in toluene as shown in the above blending ratio. Thereafter, bisoprolol was added and sufficiently stirred to obtain a coating solution. Next, after apply
- the percutaneously absorbable preparations of Comparative Examples 6 to 8 were obtained with a predetermined thickness (100 ⁇ m) and further laminated with a polyethylene terephthalate support.
- Test example 1 Drug content stability test
- the percutaneous absorption preparations produced in Examples 1, 4, 7, 10, and 13 and Comparative Examples 1 and 4 were cut into a size of 10 cm 2 to obtain samples used in the test.
- Bisoprolol or fluvoxamine content (N i ) obtained by measurement of each sample stored for 2 weeks and 1 month in a constant temperature and humidity chamber at a temperature of 60 ° C. and a humidity of 75%, and bisoprolol obtained by measurement of the initial sample
- the value (R i ) obtained by substituting the value of the content (N 0 ) of fluvoxamine into the relational expression shown in the following formula (1) is used to store bisoprolol or fluvoxamine in each sample after storage under each condition.
- the pressure-sensitive adhesive layer based on an acrylic pressure-sensitive adhesive has a large decrease in the drug content over time, but compared with that, it is based on a water-soluble polymer.
- the pressure-sensitive adhesive layer (Examples 1, 4, 7, 10 and 13) used as the agent is excellent in drug content stability.
- Test example 2 [Evaluation of the physical properties] The physical properties of the percutaneously absorbable preparations containing the bisoprolol-containing pressure-sensitive adhesive layers of Examples 1, 4, 5, 7, 8, and 10 and Comparative Examples 1, 2, 6, 7, and 8 are shown in terms of cohesive strength and bleeding. The presence or absence was evaluated.
- the transdermal preparations (Comparative Examples 6 to 8) containing a pressure-sensitive adhesive layer based on a rubber-based pressure-sensitive adhesive cause drug bleed and weak cohesion. It could not be included.
- percutaneous absorption type preparations (Comparative Examples 1 and 2) containing an adhesive layer based on an acrylic adhesive showed good physical properties.
- the percutaneous absorption-type preparation comprising an adhesive layer based on the water-soluble polymer polyvinylpyrrolidone (Examples 1, 4 and 5) or hydroxypropylcellulose (Examples 7 and 8) also has strong cohesive strength. Bleeding did not occur and the physical properties were good.
- the drug reservoir layer of the example containing the water-soluble polymer and the drug has better drug content stability than the drug reservoir layer of the comparative example.
- Hydroxypropylcellulose and polyvinylpyrrolidone were also good in terms of physical properties such as cohesive strength and bleeding.
- Test example 3 [Hairless mouse skin permeability test] The percutaneous absorption preparation (3 cm 2 ) obtained in Examples 15 and 16 or Comparative Example 9 was applied to the stratum corneum side of the skin (body side part) extracted from a 7 to 10-week-old hairless mouse, and the dermis side was The receptor layer side was attached to a flow-through type diffusion cell. On the receptor layer side, phosphate buffered saline having a pH of 7.4 was circulated so that the skin surface temperature was 32 ⁇ 1 ° C. The bisoprolol concentration was measured by a high performance liquid chromatographic method under the conditions of a receptor liquid flow rate: 4 mL / hour and sampling: every 4 hours. FIG. 1 shows the permeation rate per hour for Examples 15 and 16 and Comparative Example 9 obtained from the measured values of flow rate and bisoprolol concentration.
- Example 15 polyvinylpyrrolidone
- Example 16 hydroxypropylcellulose
- Comparative Example 9 acrylic adhesive
- Test example 4 [Human skin permeability test] Using test human skin (abdomen) with a thickness of about 500 ⁇ m from the stratum corneum side, the percutaneously absorbable preparation obtained in Example 16 or Comparative Example 9 is applied to the stratum corneum side, and the dermis side is the receptor. On the layer side, it was attached to a flow-through diffusion cell. On the receptor layer side, phosphate buffered saline having a pH of 7.4 was circulated so that the skin surface temperature was 32 ⁇ 1 ° C. The bisoprolol concentration was measured by a high performance liquid chromatographic method under the conditions of a receptor liquid flow rate: 4 mL / hour and sampling: every 4 hours.
- Example 16 showed skin permeation persistence for one week, similar to the preparation of Comparative Example 9.
- the transdermally absorbable preparation of the present invention has little decrease in drug content over time even when a high concentration of basic drug is contained in the drug reservoir layer, and has good cohesiveness, such as bleed and cold. It does not cause flow and has excellent physical properties. Furthermore, since the drug can be absorbed through the skin at a sustained and stable rate over a week, bisoprolol and fluvoxamine are extremely useful for the treatment of diseases that are effective as therapeutic agents.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
ビソプロロールは現在臨床の場において経口剤としてのみ用いられ、高β1選択性のため気管支への影響が比較的少ない。しかしながら、ビソプロロールを経口投与する場合には、徐脈、めまい、倦怠感等の症状を生ずる場合があり、長期間にわたる血中濃度の安定化および効果の持続性の観点から、経口投与よりも、むしろ貼付剤等による経皮投与製剤の開発が望まれている。
フルボキサミンもまた塩基性薬物であり、シナプスにおけるセロトニンの再吸収に作用する選択的セロトニン再取り込み阻害薬であり、抗うつ薬である。
フルボキサミンなどのSSRI(選択的セロトニン再取り込み阻害薬)は、患者に経口投与した場合に、嘔気、下痢、消化管障害などの副作用が懸念されており、さらに、服用中止等のようなコンプライアンス低下の不具合も生じている。そこで、近年では経口投与以外の投与方法が検討されている。
また、特許文献5には、選択的セロトニン再取り込み阻害成分を薬理活性成分として含有する貼付剤が提示されている。しかし同文献は、水溶性分子を貼付剤に含有させることにより、塩基性薬物を高濃度に含有せしめるものでなく、またそれを実現する手段を提供するものでもない。
さらに、特許文献6には、薬剤非透過性の裏打ち剤層、裏打ち剤層と薬剤放出層との間のセロトニン受容体拮抗薬が含有された薬剤貯留層、および薬剤の放出をコントロールし得る感圧性接着剤層からなる薬剤放出層よりなる、少なくとも3個の層を有する経皮治療用装置が開示されている。しかし同文献は、塩基性薬物を高濃度に含有せしめるものでも、またそれを実現する手段を提供するものでもない。
さらに、本発明は、粘着剤層が複数の層からなる前記経皮吸収型製剤であって、粘着剤層が、塩基性薬物および水溶性高分子を含有する薬物貯留層であって、該塩基性薬物を10~60質量%含む前記薬物貯留層と、皮膚接着層とを含む前記経皮吸収型製剤に関する。
また、本発明は、塩基性薬物がビソプロロールである前記経皮吸収型製剤に関する。
さらに、本発明は、塩基性薬物がフルボキサミンである前記経皮吸収型製剤に関する。
また、本発明は、水溶性高分子がセルロース誘導体、ポリビニルピロリドンおよびアミノアルキル(メタ)アクリレート共重合体から選択される1種または2種以上である前記経皮吸収型製剤に関する。
さらに、本発明は、セルロース誘導体がヒドロキシプロピルセルロースである前記経皮吸収型製剤に関する。
また、本発明は、薬物貯留層での薬物と水溶性高分子の重量比が 15:85 ~ 70:30 である前記経皮吸収型製剤に関する。
さらに、本発明は、皮膚接着層がスチレン-イソプレン-スチレンブロック共重合体を含有する、前記経皮吸収型製剤に関する。
また、本発明は、皮膚接着層が、スチレン-イソプレン-スチレンブロック共重合体以外の合成ゴム、粘着付与樹脂、および可塑剤からなる群から選択される1種または2種以上をさらに含有する、前記経皮吸収型製剤に関する。
さらに、本発明は、スチレン-イソプレン-スチレンブロック共重合体以外の合成ゴムが、ポリイソブチレン、イソプレンゴム、スチレン-ブタジエン-スチレン共重合体、およびスチレン-ブタジエンゴムからなる群から選択される1種または2種以上である、前記経皮吸収型製剤に関する。
また、本発明は、粘着付与樹脂が、ロジン誘導体、脂環族飽和炭化水素樹脂、脂肪族系炭化水素樹脂、テルペン樹脂、およびマレイン酸レジンからなる群から選択される1種または2種以上である、前記経皮吸収型製剤に関する。
また、本発明は、粘着剤層が、溶解剤、経皮吸収促進剤、抗酸化剤、充填剤、架橋剤、防腐剤、および紫外線吸収剤からなる群から選択される1種または2種以上をさらに含有する前記経皮吸収型製剤に関する。
さらに、本発明は、溶解剤および/または吸収促進剤が、炭素鎖数6~20の、飽和または不飽和の、環状、直鎖状または分枝状の、脂肪酸、脂肪アルコール、脂肪酸エステル、アミド、エーテル類、芳香族系有機酸、芳香族系アルコール、芳香族系有機酸エステルおよびエーテル、ならびに乳酸エステル類、酢酸エステル類、モノテルペン系化合物、セスキテルペン系化合物、エイゾン、エイゾン誘導体、ピロチオデカン、グリセリン脂肪酸エステル類、プロピレングリコール脂肪酸エステル類、ソルビタン脂肪酸エステル類(Span系)ポリソルベート系(Tween系)、ポリエチレングリコール脂肪酸エステル類、ポリオキシエチレン硬化ヒマシ油系、ポリオキシエチレンアルキルエーテル類、ショ糖脂肪酸エステル類、および植物油からなる群から選択される1種または2種以上である前記経皮吸収型製剤に関する。
また、本発明は、薬物貯留層と皮膚接着層の厚みの比が1:3~5:1である、前記経皮吸収型製剤に関する。
さらに、本発明は、薬物貯留層と皮膚接着層とを張り合わせることにより、前記経皮吸収型製剤を製造する方法に関する。
また、本発明の経皮吸収型製剤において、粘着剤層は、2層以上の複数の層に分けられ、皮膚に貼付するための支持体から最も離れている層として皮膚接着層を存在させ、支持体と皮膚接着層との間に薬物貯留層が存在させることが、薬剤の徐放性の点において好ましい。
特にポリエチレンテレフタレートからなる伸縮性または非伸縮性のシートが好ましい。
これらのうち、ビソプロロールやフルボキサミンのような、融点が低く、塩基性の薬物を多量(高濃度)に保持でき、薬物の含量安定性が良好であり、さらに、粘着剤層の物性が良好(凝集性がよく、ブリーディング・コールドフローしない)な点で、ヒドロキシプロピルセルロース、ポリビニルピロリドン、アミノアルキル(メタ)アクリレート共重合体が好ましく用いられる。
なお、本発明の粘着剤層は、水や炭素数1~6の低級アルコールを含有しないことが物性(凝集性がよく、ブリーディング・コールドフローしない)を確保できるため好ましい。
また、水溶性高分子の分子量(表示粘度)は、凝集力や硬さなどの粘着剤層の物性に影響する。特にヒドロキシプロピルセルロースの分子量(表示粘度)は、1.0mPa・s~4000mPa・s、より好ましくは、1.0mPa・s~400mPa・sの範囲がよい。
本発明の経皮吸収型製剤に用いられる薬物としては、上記薬物の中でも血圧降下剤(α遮断薬、β遮断薬、Ca拮抗薬、ACE阻害薬、アンギオテンシンII受容体拮抗薬)が好ましく、特にβ遮断薬が好ましく、中でもビソプロロールが本発明の効果が顕著であるため最も好ましい。
また、本発明の経皮吸収型製剤に用いられる薬物としては、上記薬物の中でも精神神経用剤(抗精神病薬、抗うつ薬、抗躁薬、抗不安薬)が好ましく、特に抗うつ薬が好ましく、中でもフルボキサミンなどの選択的セロトニン再取り込み阻害薬が本発明の効果が顕著であるため最も好ましい。
さらに薬物は遊離塩基あるいは薬理学的に許容される塩として用いられる。
薬理学的に許容される塩としては、特に限定されないが、例えば、塩酸塩、臭化水素酸塩、硝酸塩、硫酸塩、リン酸塩、ギ酸塩、酢酸塩、トリフルオロ酢酸塩、プロピオン酸塩、乳酸塩、酒石酸塩、シュウ酸塩、フマル酸塩、マレイン酸塩、クエン酸塩、マロン酸塩、メタンスルホン酸塩等が挙げられる。
薬物は薬物貯留層中に溶解状態、過飽和結晶状態または分散状態にて含有させることができる。
本発明の経皮吸収型製剤に配合される薬物の含有量が、粘着剤層または薬物貯留層の全量を基準として10質量%以下であると、製剤の投与期間にわたり、充分な薬物の皮膚透過性が得られないため好ましくない場合があり、また、60質量%以上であると貼付剤としての充分な凝集力を維持できない場合や含量安定性が低下する場合がある。本経皮吸収型製剤は、水溶性高分子を含有するため、極性の高いビソプロロール、フルボキサミンなどの塩基性薬物、またはそれらの薬学的に許容できる塩を大量保持することができると共に、含量低下が少ない。
皮膚接着層の基剤としては、特に限定されないが、例えば、ゴム系粘着剤、シリコーン系粘着剤、アクリル粘着剤等を用いることができるが、ゴム系粘着剤を粘着成分として含むことが好ましい。このゴム系の粘着成分としては、スチレン-イソプレン-スチレンブロック共重合体が特に好適に用いられる。
スチレン-イソプレン-スチレンブロック共重合体の皮膚接着層に対する含有量は、5質量%以下であると貼付剤として充分な透過性および凝集力を維持できない傾向があり、30質量%以上であると貼付剤として充分な粘着力を維持できなくなるため、5~30質量%が好ましい。
さらに、本発明においては、必要に応じて、薬物貯留層および/または皮膚接着層中に、溶解剤、経皮吸収促進剤、抗酸化剤、充填剤、架橋剤、防腐剤、紫外線吸収剤等を配合することができる。
溶解剤としては薬物に対して溶解作用を有する化合物であればいずれでもよい。また、吸収促進剤としては、従来皮膚で吸収促進作用が認められている化合物のいずれでもよい。
また、本発明の経皮吸収型製剤は、支持体と薬物貯留層との間や、薬物貯留層と皮膚接着層との間に、例えば、特に限定されないが、アクリル系粘着剤、ゴム系粘着剤、水溶性高分子、放出制御膜などの更なる層を設けることもできる。
薬物貯留層の厚みは、治療量の薬物を所定の期間(1~7日間)投与するために十分な量を含有、保持させることが可能であれば制限はないが、25~400μmが好ましく、50~300μmがより好ましい。
また、薬物貯留層と皮膚接着層を合わせた粘着剤層全体の厚みは、特に制限はないが、違和感なく、快適に貼付することができる点で、35~600μmが好ましく、70~450μmがより好ましい。
さらに、薬物貯留層と皮膚接着層の厚みの比は、製剤の安定性、薬物の放出制御、貼付性を考慮して任意に設定できるが、通常、1:5~5:1が良く、より好ましくは1:3~5:1の範囲が良い。
上記処方表に示す配合比となるように、それぞれのポリマーにエタノールを加え溶解させた後、ビソプロロールまたはフルボキサミンを加えて十分に攪拌し、塗工液を得た。次に、得られた塗工液をポリエチレンテレフタレート製離型フィルム上に塗布した後、溶媒であるエタノールを乾燥除去して、粘着剤層を形成した。所定の厚み(200μm)とし、さらに、ポリエチレンテレフタレート製支持体と張り合わせて、本発明の経皮吸収型製剤(実施例1~14)を得た。
アクリル粘着剤溶液(-COOH基含有タイプまたは-OH基含有タイプ、溶媒:酢酸エチル・トルエン)にビソプロロールまたフルボキサミンを加え、十分に攪拌し塗工液を得た。次に、得られた塗工液をポリエチレンテレフタレート製離型フィルム上に塗布した後、溶媒である酢酸エチルおよびトルエンを乾燥除去して、粘着剤層を形成した。所定の厚み(200μm)とし、さらに、ポリエチレンテレフタレート製支持体と張り合わせて、比較例1~5の経皮吸収型製剤を得た。
上記処方表に示す配合比の通り、スチレン-イソプレン-スチレンブロック共重合体、ポリイソブチレン(高分子量)、ポリイソブチレン(低分子量)、脂環族飽和炭化水素樹脂、流動パラフィンをトルエンに溶解させた後、ビソプロロールを加えて十分に攪拌し塗工液を得た。次に、得られた塗工液をポリエチレンテレフタレート製離型フィルム上に塗布した後、溶剤を乾燥除去して、粘着剤層を形成した。所定の厚み(100μm)とし、さらに、ポリエチレンテレフタレート製支持体と張り合わせて、比較例6~8の経皮吸収型製剤を得た。
[薬物含量安定性試験]
実施例1、4、7、10、および13ならびに比較例1および4にて製造した経皮吸収型製剤を10cm2の大きさに裁断し、試験に用いるサンプルを得た。温度60℃、湿度75%の恒温恒湿槽中に2週間および1ヶ月保存した各サンプルの測定により得られたビソプロロールまたはフルボキサミンの含有量(Ni)、および初期サンプルの測定で得られたビソプロロールまたはフルボキサミンの含有量(N0)の値を、下記式(1)に示す関係式に代入して得られた値(Ri)を、各サンプルにおけるビソプロロールまたはフルボキサミンの、各条件における保管後の対初期値(%)とした。
Ri(%)=Ni/N0×100 …(1)
(抽出方法)
粘着剤層、テトラハイドロフラン(10mL)を遠沈管に入れ、1時間振とうした。これに、内部標準物質(4-アミノ安息香酸イソプロピル/メタノール溶液)を加えた後、メタノールで50mLに調整し、更に1時間振とうした。次いで、高速液体クロマトグラフィーにより各試験サンプルにおけるビソプロロールまたはフルボキサミンの含量を定量した。
[物性評価]
実施例1、4、5、7、8および10、ならびに比較例1、2、6、7および8のビソプロロール含有粘着剤層を含む経皮吸収型製剤の物性を、凝集力の強さとブリーディングの有無について評価した。
実施例15および16、比較例9
[皮膚接着層処方]
次に、実施例4および7、ならびに比較例1で得られた粘着剤層を薬物貯留層として皮膚接着層と接合し、実施例15および16、ならびに比較例9の経皮吸収型製剤を得た。
[ヘアレスマウス皮膚透過性試験]
7~10週齢のヘアレスマウスより摘出した皮膚(体側部)の角質層側に実施例15、16または比較例9において得られた経皮吸収型製剤(3cm2)を貼付し、真皮側をレセプター層側にして、フロースルー型拡散セルに装着した。そして、レセプター層側はpH 7.4のリン酸緩衝生理食塩水を、皮膚表面温度が32±1℃となるように循環させた。レセプター液流速:4mL/時間、サンプリング:4時間毎の条件で、高速液体クロマトグラフ法によりビソプロロール濃度を測定した。
図1に流量およびビソプロロール濃度の測定値より求めた、実施例15および16、ならびに比較例9の1時間あたりの透過速度を示す。
[ヒト皮膚透過性試験]
角質層側から約500μmの厚みとした、試験用のヒト皮膚(腹部)を用い、角質層側に実施例16または比較例9において得られた経皮吸収型製剤を貼付し、真皮側をレセプター層側にして、フロースルー型拡散セルに装着した。そして、レセプター層側はpH 7.4のリン酸緩衝生理食塩水を、皮膚表面温度が32±1℃となるように循環させた。レセプター液流速:4mL/時間、サンプリング:4時間毎の条件で、高速液体クロマトグラフ法によりビソプロロール濃度を測定した。
Claims (16)
- 支持体と粘着剤層とを有する経皮吸収型製剤であって、粘着剤層が、塩基性薬物および水溶性高分子を含有する、前記経皮吸収型製剤。
- 粘着剤層が複数の層からなる請求項1に記載の経皮吸収型製剤であって、粘着剤層が、塩基性薬物および水溶性高分子を含有する薬物貯留層であって、該塩基性薬物を10~60質量%含む前記薬物貯留層と、皮膚接着層とを含む、前記経皮吸収型製剤。
- 塩基性薬物がビソプロロールである、請求項1または2の経皮吸収型製剤。
- 塩基性薬物がフルボキサミンである、請求項1または2の経皮吸収型製剤。
- 水溶性高分子がセルロース誘導体、ポリビニルピロリドンおよびアミノアルキル(メタ)アクリレート共重合体から選択される1種または2種以上である、請求項1~4のいずれか1項に記載の経皮吸収型製剤。
- セルロース誘導体がヒドロキシプロピルセルロースである、請求項5に記載の経皮吸収型製剤。
- 薬物貯留層での薬物と水溶性高分子の重量比が 15:85 ~ 70:30 である、請求項2~6のいずれか1項に記載の経皮吸収型製剤。
- 皮膚接着層がスチレン-イソプレン-スチレンブロック共重合体を含有する、請求項2~7のいずれか1項に記載の経皮吸収型製剤。
- 皮膚接着層が、スチレン-イソプレン-スチレンブロック共重合体以外の合成ゴム、粘着付与樹脂、および可塑剤からなる群から選択される1種または2種以上をさらに含有する、請求項8に記載の経皮吸収型製剤。
- スチレン-イソプレン-スチレンブロック共重合体以外の合成ゴムが、ポリイソブチレン、イソプレンゴム、スチレン-ブタジエン-スチレン共重合体、およびスチレン-ブタジエンゴムからなる群から選択される1種または2種以上である、請求項9に記載の経皮吸収型製剤。
- 粘着付与樹脂が、ロジン誘導体、脂環族飽和炭化水素樹脂、脂肪族系炭化水素樹脂、テルペン樹脂、およびマレイン酸レジンからなる群から選択される1種または2種以上である、請求項9または10に記載の経皮吸収型製剤。
- 可塑剤が、石油系オイル、スクワラン、スクワレン、植物系オイル、シリコンオイル、二塩基酸エステル、液状ゴム、液状脂肪酸エステル類、ジエチレングリコール、ポリエチレングリコール、サリチル酸グリコール、プロピレングリコール、ジプロピレングリコール、トリアセチン、クエン酸トリエチル、およびクロタミトンからなる群から選択される1種または2種以上である、請求項9~11のいずれか1項に記載の経皮吸収型製剤。
- 粘着剤層が、溶解剤、経皮吸収促進剤、抗酸化剤、充填剤、架橋剤、防腐剤、および紫外線吸収剤からなる群から選択される1種または2種以上をさらに含有する、請求項1~12のいずれか1項に記載の経皮吸収型製剤。
- 溶解剤および/または吸収促進剤が、炭素鎖数6~20の、飽和または不飽和の、環状、直鎖状または分枝状の、脂肪酸、脂肪アルコール、脂肪酸エステル、アミド、エーテル類、芳香族系有機酸、芳香族系アルコール、芳香族系有機酸エステルおよびエーテル、ならびに乳酸エステル類、酢酸エステル類、モノテルペン系化合物、セスキテルペン系化合物、エイゾン、エイゾン誘導体、ピロチオデカン、グリセリン脂肪酸エステル類、プロピレングリコール脂肪酸エステル類、ソルビタン脂肪酸エステル類(Span系)ポリソルベート系(Tween系)、ポリエチレングリコール脂肪酸エステル類、ポリオキシエチレン硬化ヒマシ油系、ポリオキシエチレンアルキルエーテル類、ショ糖脂肪酸エステル類、および植物油からなる群から選択される1種または2種以上である、請求項13に記載の経皮吸収型製剤。
- 薬物貯留層と皮膚接着層の厚みの比が1:3~5:1である、請求項2~14のいずれか1項に記載の経皮吸収型製剤。
- 薬物貯留層と皮膚接着層とを張り合わせることにより、請求項2~15のいずれか1項に記載の経皮吸収型製剤を製造する方法。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020117026980A KR101725832B1 (ko) | 2009-05-01 | 2010-04-30 | 경피 흡수형 제제 |
EP10769822.7A EP2425827B1 (en) | 2009-05-01 | 2010-04-30 | Transdermal preparation |
JP2011511463A JP5758290B2 (ja) | 2009-05-01 | 2010-04-30 | 経皮吸収型製剤 |
CN2010800185737A CN102413821A (zh) | 2009-05-01 | 2010-04-30 | 经皮吸收型制剂 |
ES10769822.7T ES2645038T3 (es) | 2009-05-01 | 2010-04-30 | Preparado transdérmico |
US13/318,370 US8512742B2 (en) | 2009-05-01 | 2010-04-30 | Transdermal preparation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009-112234 | 2009-05-01 | ||
JP2009112234 | 2009-05-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010126124A1 true WO2010126124A1 (ja) | 2010-11-04 |
Family
ID=43032267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/057659 WO2010126124A1 (ja) | 2009-05-01 | 2010-04-30 | 経皮吸収型製剤 |
Country Status (8)
Country | Link |
---|---|
US (1) | US8512742B2 (ja) |
EP (1) | EP2425827B1 (ja) |
JP (1) | JP5758290B2 (ja) |
KR (1) | KR101725832B1 (ja) |
CN (1) | CN102413821A (ja) |
ES (1) | ES2645038T3 (ja) |
TW (1) | TWI552773B (ja) |
WO (1) | WO2010126124A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012077651A1 (ja) * | 2010-12-07 | 2012-06-14 | 祐徳薬品工業株式会社 | ノルアドレナリン作動性・特異的セロトニン作動性抗うつ薬含有経皮吸収型貼付製剤 |
CN102634307A (zh) * | 2012-05-03 | 2012-08-15 | 河南羚锐制药股份有限公司 | 一种热熔压敏胶及其制备方法 |
JP2017039706A (ja) * | 2015-08-19 | 2017-02-23 | ニチバン株式会社 | 皮膚貼付用ハイドロコロイド型粘着剤組成物、及びこれを用いた貼付材 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2968652B1 (en) | 2013-03-13 | 2020-07-22 | Avery Dennison Corporation | Improving adhesive properties |
EP2921184A1 (de) * | 2014-03-19 | 2015-09-23 | LTS LOHMANN Therapie-Systeme AG | Überpflaster mit verbesserter Verträglichkeit und einer langen Haftungsdauer und Verfahren zu seiner Herstellung |
CN109922796B (zh) | 2016-06-23 | 2023-04-07 | 考里安有限责任公司 | 具有亲水和疏水域的粘合剂基质和治疗剂 |
KR102424270B1 (ko) | 2016-07-27 | 2022-07-25 | 코리움, 인크. | 경구 전달과 생물학적으로 동등한 약물동역학을 가진 경피 전달 시스템 |
RU2764764C2 (ru) | 2016-07-27 | 2022-01-21 | Кориум Интернэшнл, Инк. | Трансдермальные системы доставки мемантина |
EP3490541A2 (en) | 2016-07-27 | 2019-06-05 | Corium International, Inc. | Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs byin situ |
MX2019007391A (es) | 2016-12-20 | 2019-08-16 | Lts Lohmann Therapie Systeme Ag | Sistema terapeutico transdermico que contiene asenapina. |
EP3558276A1 (en) | 2016-12-20 | 2019-10-30 | LTS Lohmann Therapie-Systeme AG | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
JPWO2018124043A1 (ja) * | 2016-12-28 | 2019-10-31 | 小林製薬株式会社 | 外用組成物 |
JP7116041B2 (ja) | 2017-03-16 | 2022-08-09 | フクダ電子株式会社 | 生体用電極シート |
KR20180121352A (ko) | 2017-04-28 | 2018-11-07 | 닛토덴코 가부시키가이샤 | 경피 흡수형 제제 |
JP2020525545A (ja) | 2017-06-26 | 2020-08-27 | エルテーエス ローマン テラピー−ジステーメ アーゲー | アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム |
KR101842976B1 (ko) * | 2017-12-07 | 2018-03-29 | (주)아모레퍼시픽 | 점착성 탄력 미용 밴드 |
WO2019126531A1 (en) | 2017-12-20 | 2019-06-27 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
AU2019291060B2 (en) | 2018-06-20 | 2024-09-05 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59184120A (ja) * | 1983-03-31 | 1984-10-19 | Nitto Electric Ind Co Ltd | アクリル系膏体 |
JPS61501324A (ja) * | 1984-03-01 | 1986-07-03 | サンド・アクチエンゲゼルシヤフト | 医薬組成物 |
JPH04305523A (ja) * | 1991-03-30 | 1992-10-28 | Teikoku Seiyaku Co Ltd | リドカイン含有外用貼付剤 |
JPH09509960A (ja) * | 1994-03-07 | 1997-10-07 | セラテック・インコーポレーテッド | 薬剤含有接着複合体の経皮放出デバイス |
WO1998025592A1 (fr) | 1996-12-11 | 1998-06-18 | Hisamitsu Pharmaceutical Co., Inc. | Preparation transdermique contenant un antagoniste des recepteurs de la serotonine |
JP2003313122A (ja) | 2002-04-19 | 2003-11-06 | Nitto Denko Corp | ビソプロロール含有貼付剤 |
US20040170673A1 (en) * | 2001-04-12 | 2004-09-02 | Andreas Koch | Adhesive emulsion for medical purposes made from ethylene-vinyl acetate copolymers and adhesive resins |
JP2007099759A (ja) | 2005-09-09 | 2007-04-19 | Nitto Denko Corp | ビソプロロール含有貼付製剤 |
WO2007099966A1 (ja) | 2006-02-28 | 2007-09-07 | Hisamitsu Pharmaceutical Co., Inc. | 経皮吸収型製剤 |
JP2007284378A (ja) | 2006-04-17 | 2007-11-01 | Saitama Daiichi Seiyaku Kk | 選択的セロトニン再取込阻害成分を含有する製剤 |
JP2008247899A (ja) | 2007-03-08 | 2008-10-16 | Nitto Denko Corp | ビソプロロール経皮投与デバイス |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5364628A (en) | 1985-05-31 | 1994-11-15 | Sandoz Ltd. | Pharmaceutical compositions |
US4820525A (en) * | 1987-09-17 | 1989-04-11 | American Home Products Corporation (Del.) | Transdermal drug delivery system |
SU1705319A1 (ru) * | 1987-10-23 | 1992-01-15 | Всесоюзный Научно-Исследовательский Институт Биотехнологии | Состав полимерной диффузионной матрицы дл трансдермального введени лекарственных веществ |
JP4346696B2 (ja) * | 1996-05-28 | 2009-10-21 | 久光製薬株式会社 | 経皮治療用装置 |
US6448303B1 (en) * | 2000-12-29 | 2002-09-10 | National Starch And Chemical Investment Holding Corporation | Hot melt adhesives for dermal application |
JP4694967B2 (ja) * | 2003-07-31 | 2011-06-08 | 久光製薬株式会社 | 貼付剤 |
CA2522152A1 (en) * | 2004-10-07 | 2006-04-07 | Kabushiki Kaisha Sangi | Transdermal and transmucosal preparations |
WO2007065303A1 (fr) | 2005-12-09 | 2007-06-14 | Beijing Kangbeide Pharmaceutical Technology Development Co., Ltd. | Timbre transdermique a base de dinitrate d'isosorbide et de bisoprolol |
JP5037831B2 (ja) * | 2006-02-15 | 2012-10-03 | 久光製薬株式会社 | 凝集力向上及び徐放化の外用貼付剤 |
US9248104B2 (en) * | 2006-08-17 | 2016-02-02 | Core Tech Solutions, Inc. | Transdermal methods and systems for treating Alzheimer's disease |
WO2009026133A2 (en) * | 2007-08-17 | 2009-02-26 | Alza Corporation | Transdermal bisoprolol delivery system |
WO2009026135A2 (en) | 2007-08-17 | 2009-02-26 | Alza Corporation | Controlled transdermal bisoprolol delivery system |
-
2010
- 2010-04-30 US US13/318,370 patent/US8512742B2/en active Active
- 2010-04-30 ES ES10769822.7T patent/ES2645038T3/es active Active
- 2010-04-30 KR KR1020117026980A patent/KR101725832B1/ko active IP Right Grant
- 2010-04-30 EP EP10769822.7A patent/EP2425827B1/en active Active
- 2010-04-30 CN CN2010800185737A patent/CN102413821A/zh active Pending
- 2010-04-30 JP JP2011511463A patent/JP5758290B2/ja active Active
- 2010-04-30 WO PCT/JP2010/057659 patent/WO2010126124A1/ja active Application Filing
- 2010-04-30 TW TW099113982A patent/TWI552773B/zh not_active IP Right Cessation
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59184120A (ja) * | 1983-03-31 | 1984-10-19 | Nitto Electric Ind Co Ltd | アクリル系膏体 |
JPS61501324A (ja) * | 1984-03-01 | 1986-07-03 | サンド・アクチエンゲゼルシヤフト | 医薬組成物 |
JPH04305523A (ja) * | 1991-03-30 | 1992-10-28 | Teikoku Seiyaku Co Ltd | リドカイン含有外用貼付剤 |
JPH09509960A (ja) * | 1994-03-07 | 1997-10-07 | セラテック・インコーポレーテッド | 薬剤含有接着複合体の経皮放出デバイス |
WO1998025592A1 (fr) | 1996-12-11 | 1998-06-18 | Hisamitsu Pharmaceutical Co., Inc. | Preparation transdermique contenant un antagoniste des recepteurs de la serotonine |
US20040170673A1 (en) * | 2001-04-12 | 2004-09-02 | Andreas Koch | Adhesive emulsion for medical purposes made from ethylene-vinyl acetate copolymers and adhesive resins |
JP2003313122A (ja) | 2002-04-19 | 2003-11-06 | Nitto Denko Corp | ビソプロロール含有貼付剤 |
JP2007099759A (ja) | 2005-09-09 | 2007-04-19 | Nitto Denko Corp | ビソプロロール含有貼付製剤 |
WO2007099966A1 (ja) | 2006-02-28 | 2007-09-07 | Hisamitsu Pharmaceutical Co., Inc. | 経皮吸収型製剤 |
JP2007284378A (ja) | 2006-04-17 | 2007-11-01 | Saitama Daiichi Seiyaku Kk | 選択的セロトニン再取込阻害成分を含有する製剤 |
JP2008247899A (ja) | 2007-03-08 | 2008-10-16 | Nitto Denko Corp | ビソプロロール経皮投与デバイス |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012077651A1 (ja) * | 2010-12-07 | 2012-06-14 | 祐徳薬品工業株式会社 | ノルアドレナリン作動性・特異的セロトニン作動性抗うつ薬含有経皮吸収型貼付製剤 |
JP5073124B2 (ja) * | 2010-12-07 | 2012-11-14 | 祐徳薬品工業株式会社 | ノルアドレナリン作動性・特異的セロトニン作動性抗うつ薬含有経皮吸収型貼付製剤 |
CN102634307A (zh) * | 2012-05-03 | 2012-08-15 | 河南羚锐制药股份有限公司 | 一种热熔压敏胶及其制备方法 |
JP2017039706A (ja) * | 2015-08-19 | 2017-02-23 | ニチバン株式会社 | 皮膚貼付用ハイドロコロイド型粘着剤組成物、及びこれを用いた貼付材 |
Also Published As
Publication number | Publication date |
---|---|
KR20120023658A (ko) | 2012-03-13 |
KR101725832B1 (ko) | 2017-04-11 |
JP5758290B2 (ja) | 2015-08-05 |
JPWO2010126124A1 (ja) | 2012-11-01 |
EP2425827A1 (en) | 2012-03-07 |
EP2425827B1 (en) | 2017-07-26 |
US20120058175A1 (en) | 2012-03-08 |
ES2645038T3 (es) | 2017-12-01 |
EP2425827A4 (en) | 2013-07-10 |
TW201105368A (en) | 2011-02-16 |
TWI552773B (zh) | 2016-10-11 |
CN102413821A (zh) | 2012-04-11 |
US8512742B2 (en) | 2013-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5758290B2 (ja) | 経皮吸収型製剤 | |
JP5190358B2 (ja) | 経皮吸収型製剤 | |
JP5075334B2 (ja) | 薬物含有貼付剤 | |
JPWO2005115355A1 (ja) | 貼付製剤 | |
KR20050042014A (ko) | 적층 지지체를 갖는 부착제 | |
JP5404048B2 (ja) | 貼付剤 | |
WO2010098261A1 (ja) | リスペリドン含有経皮吸収型製剤及びこれを用いた貼付剤 | |
EP2514424A1 (en) | Piroxicam-containing endermic preparation | |
WO2016208729A1 (ja) | ナルフラフィン含有経皮吸収貼付剤 | |
EP2514419B1 (en) | Felbinac-containing transdermal absorption preparation | |
JP6675589B2 (ja) | 経皮吸収型製剤 | |
WO2018104772A1 (ja) | 経皮吸収型製剤 | |
JP6220893B2 (ja) | クロニジン含有貼付剤 | |
WO2018155682A1 (ja) | リバスチグミン含有経皮吸収型製剤 | |
JPWO2013140799A1 (ja) | 経皮吸収型製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080018573.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10769822 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2011511463 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13318370 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20117026980 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8442/CHENP/2011 Country of ref document: IN |
|
REEP | Request for entry into the european phase |
Ref document number: 2010769822 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010769822 Country of ref document: EP |